Zealand Pharma's 'More Commercial' CEO Jensen On Lixisenatide And Beyond

Danish company Zealand Pharma, most noteworthy for developing the thus far commercially disappointing Sanofi-partnered GLP-1 receptor agonist Lyxumia (lixisenatide), appointed its new CEO a year ago, claiming it needed someone with a more commercial focus. Scrip caught up with Britt Meelby Jensen to find out what lessons the company has learned from the Lyxumia episode and how Zealand Pharma is moving beyond diabetes.